OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Receipt of deferred consideration
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.
Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
| Omega Diagnostics Group PLC | ||
| Jag Grewal, Chief Executive | via Walbrook PR | |
| Chris Lea, Chief Financial Officer | | |
| | | |
| finnCap Ltd | Tel: 020 7220 0500 | |
| Geoff Nash/Edward Whiley (Corporate Finance) | | |
| Alice Lane/ Harriet Ward (ECM) | | |
| | | |
| Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com | |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / Mob: 07502 558 258 | |
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.